Alzheimer Disease: all 3,765 studies

Page 34 of 38. Open to participants first (881), then studies with results posted, then the rest; newest registration first within each.

• Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed DementiaCompletedNCT01023867Not applicable
• To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsCompletedNCT01023685Phase 2
• Clinical Trial of Donepezil Between the Naive Group and the Switching GroupCompletedNCT01023425Not applicable
• Genes, Exercise, Memory and NeurodegenerationCompletedNCT01021644Not applicable
• Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's DiseaseCompletedNCT01019421Phase 2
• Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's DiseaseCompletedNCT01018875Phase 2
• An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's DiseaseCompletedNCT01013610Phase 1
• Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily RoutineCompletedNCT01009476
• Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy VolunteersCompletedNCT01009359Phase 1
• Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's DiseaseCompletedNCT01009255Phase 2
• Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy VolunteersCompletedNCT01005862Phase 1
• Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's DementiaCompletedNCT01002586Not applicable
• Drug-Drug Interaction Study With RifampinCompletedNCT01002079Phase 1
• Efficacy and Safety of Curcumin Formulation in Alzheimer's DiseaseTerminatedNCT01001637Not applicable
• Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513TerminatedNCT01000870Early Phase 1
• Wii-fit for Activity, Balance and Gait in Assisted LivingCompletedNCT01000038Not applicable
• To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid BurdenCompletedNCT00991419Phase 2
• A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The SkinCompletedNCT00990613Phase 1
• A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)CompletedNCT00988624Phase 1
• Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal FluidCompletedNCT00987220
• Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)Status unknownNCT00987090Not applicable
• Pioglitazone in Alzheimer DiseaseCompletedNCT00982202Phase 2
• Passport to Brain Wellness in Sedentary AdultsCompletedNCT00979446Not applicable
• Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy SubjectsCompletedNCT00979316Phase 1
• Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's DiseaseCompletedNCT00976118Phase 2
• Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)CompletedNCT00973518
• Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological ConditionsCompletedNCT00970333Phase 1
• Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein DepositionTerminatedNCT00968097Phase 1
• Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and DementiaStatus unknownNCT00966017
• Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down SyndromeStatus unknownNCT00965835
• Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's DiseaseCompletedNCT00965588Phase 1
• To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsCompletedNCT00956410Phase 2
• Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's DiseaseCompletedNCT00955422
• Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the ElderlyCompletedNCT00954616
• A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's DiseaseTerminatedNCT00954590Phase 3
• Exploratory and Safety Study of [F-18]W372CompletedNCT00954369Early Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male SubjectsCompletedNCT00954252Phase 1
• Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s DiseaseCompletedNCT00951834Phase 2/3
• Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly SubjectsCompletedNCT00951197
• Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's DiseaseCompletedNCT00948909Phase 2
• Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s DiseaseCompletedNCT00948259Phase 1/2
• Study of the Brain Stimulation Effect on Memory Impairment in Alzheimer DiseaseWithdrawnNCT00947934Not applicable
• Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.CompletedNCT00938665
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedNCT00937352Phase 3
• A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 MetabolizersCompletedNCT00931073Phase 1
• Rajavtihi Neuronal Adult Stem Cells ProjectWithdrawnNCT00927108Phase 2
• Cataract Removal and Alzheimer's DiseaseCompletedNCT00921297Not applicable
• Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's DiseaseCompletedNCT00912886
• Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive DisordersCompletedNCT00911690
• Effects of Transcranial Magnetic Stimulation (TMS) and Cognitive Training for Alzheimer PatientsCompletedNCT00909285Not applicable
• Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)CompletedNCT00908999
• Supporting Caregivers of Persons With Dementia: A Pilot StudyCompletedNCT00908492Phase 2/3
• Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male SubjectsCompletedNCT00906191Phase 1
• Effect of LY2062430 on the Progression of Alzheimer's DiseaseCompletedNCT00905372Phase 3
• Effect of LY2062430 on the Progression of Alzheimer's DiseaseCompletedNCT00904683Phase 3
• Evolution of Memory Related ActivityStatus unknownNCT00902499
• Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's DiseaseCompletedNCT00901498Phase 1
• Implications of Amyloid PathologyStatus unknownNCT00900770
• A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's DiseaseTerminatedNCT00890890Phase 2
• Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's DiseaseStatus unknownNCT00888056Phase 1/2
• Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's DiseaseTerminatedNCT00886951Phase 1
• QTc Study of Rosi XR in Healthy VolunteersWithdrawnNCT00884533Phase 1
• A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00884507Phase 2
• Development and Decline of Brain and Cognition Through the Life SpanCompletedNCT00880451
• A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's DiseaseCompletedNCT00880412Phase 2
• Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of DementiaCompletedNCT00880347Not applicable
• Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT00876863Phase 2
• A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric ConditionsCompletedNCT00870974Phase 1
• Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy SubjectsTerminatedNCT00870519Phase 1
• Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)CompletedNCT00867828Phase 4
• A Safety and Tolerability Study of ABT-126 in ElderlyCompletedNCT00867399Phase 1
• Donepezil and Memantine in Moderate to Severe Alzheimer's DiseaseStatus unknownNCT00866060Phase 4
• Drug-Drug Interaction (DDI) w/Ketoconazole or FluconazoleCompletedNCT00860275Phase 1
• Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy BodiesCompletedNCT00855686Phase 4
• Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's DiseaseCompletedNCT00842816Phase 2
• Preliminary Efficacy and Safety Study of ST101 in Alzheimer's DiseaseCompletedNCT00842673Phase 2
• Life From Vision in Alzheimer DiseaseCompletedNCT00838942
• Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ AmyloidCompletedNCT00838877Phase 1
• A Safety Study of LY2811376 Single Doses in Healthy SubjectsCompletedNCT00838084Phase 1
• Evaluation of Apathy Using Attentional Reaction Test in Neurodegenerative DiseasesCompletedNCT00833274Not applicable
• Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy SubjectsCompletedNCT00831506Phase 1
• Assessment of Sleep Disturbance in Alzheimer DiseaseCompletedNCT00831298Not applicable
• Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus DonepezilCompletedNCT00829816Phase 1
• Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on DonepezilCompletedNCT00829374Phase 3
• A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsCompletedNCT00827034Phase 1
• A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy SubjectsCompletedNCT00825084Phase 1
• Non Pharmacological Management of Behavioural Symptoms in Nursing HomeTerminatedNCT00824967Not applicable
• A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal FunctionCompletedNCT00824590Phase 1
• Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal ElderlyTerminatedNCT00811122Early Phase 1
• A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00810147Phase 2
• A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 StudyTerminatedNCT00809510Phase 2
• Memantine and Validation of a New Alzheimer's Disease ScaleCompletedNCT00804271Phase 3
• Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's DiseaseCompletedNCT00800709Phase 4
• Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789CompletedNCT00795730Phase 1
• Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's PatientsCompletedNCT00795418Phase 2
• Improving Function, Quality of Life, Glycemia in Diabetics With DementiaWithdrawnNCT00792662Phase 4
• A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of DextromethorphanCompletedNCT00788047Phase 1
• Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy VolunteersCompletedNCT00785759Phase 2
• Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy VolunteersTerminatedNCT00777361Phase 1
• A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.CompletedNCT00765115Phase 1

← Alzheimer Disease overview